BiotechTube
Range Biotechnologies

Range Biotechnologies

San Francisco, United States· Est.
range.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Range Biotechnologies, founded in 2021 and based in San Carlos, California, is a private, pre-revenue biotech startup operating in the gene therapy and genomics sectors with a core focus on proteomics. The company is building a platform for translational proteomics, positioning itself to create new standards for diagnostics research by making high-throughput protein analysis clinically actionable. It has gained recognition as an innovative startup, being named an Innovation AveNEW company at SLAS 2025, and is actively seeking strategic partners and investors to advance its technology.

Gene TherapyGenetics & Genomics

Technology Platform

End-to-end solution for translational proteomics, focusing on high-throughput protein analysis and data interpretation to bridge research and clinical applications.

Opportunities

The growing demand for preventive health and personalized medicine creates a large market for tools that provide deep molecular monitoring.
The translational gap in proteomics represents a significant white space for a platform that can reliably move protein analysis from the lab to the clinic.
Partnerships with pharma for biomarker discovery or with diagnostic companies could provide early validation and revenue streams.

Risk Factors

The company faces intense competition from well-capitalized players in the proteomics and diagnostics tools space.
The technical hurdles to creating a robust, scalable, and clinically validated end-to-end platform are extremely high.
As a pre-revenue startup, it is vulnerable to funding shortages and must successfully navigate future financing rounds.

Competitive Landscape

Range Bio competes in the crowded and fast-evolving proteomics landscape, facing large incumbent tool providers (e.g., Thermo Fisher, Bruker) and specialized proteomics companies like Olink (acquired by Thermo Fisher), SomaLogic, and Nautilus Biotechnology. Its differentiation hinges on claiming an 'end-to-end' translational solution, but it must prove superior utility, simplicity, or cost-effectiveness against established and emerging alternatives.

More companies in Diagnostics & Precision Medicine →More companies in United States →